ArticleJournal of cachexia, sarcopenia and muscle2024
Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.
Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis.Hepatology international · 2025Pooled it
- Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Prognostic role of myosteatosis in predicting MACE and mortality after TAVR: insights from CT-based body composition analysis.The journal of nutrition, health & aging · 2026Article
- Longitudinal CT-Based Assessment of Muscle and Bone Changes After Liver Transplantation in Hepatitis B Patients with and Without Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Impact of body composition on prognostic stratification and survival in periampullary carcinoma after pancreatoduodenectomy.Abdominal radiology (New York) · 2026Article
- Article
- Myosteatosis: Epidemiological Insights, Functional Decline, and Diagnostic Advances.Current obesity reports · 2025Review
- Low Cystatin C-to-Creatinine Estimated GFR Ratio Predicts Post-Kidney Transplant Cardiovascular Events.Kidney international reports · 2025Article
- Changes in nutritional status in hepatocellular carcinoma patients treated with sorafenib.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Article
- Comment on "Myosteatosis and Muscle Loss Impact Liver Transplant Outcomes in Male Patients With Hepatocellular Carcinoma" by Lu et al.-The Authors' Reply.Journal of cachexia, sarcopenia and muscle · 2025Article
- Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy.Frontiers in nutrition · 2025Article
- Sarcopenia in liver transplantation: A comprehensive bibliometric study of current research trends and future directions.Open life sciences · 2025Article
- Molecular Mechanisms of Ischemia/Reperfusion Injury and Graft Dysfunction in Liver Transplantation: Insights from Multi-Omics Studies in Rodent Animal Models.International journal of biological sciences · 2025Review
- Comment on 'Myosteatosis and Muscle Loss Impact Liver Transplant Outcomes in Male Patients With Hepatocellular Carcinoma' by Lu et al.Journal of cachexia, sarcopenia and muscle · 2024Article
- Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.Journal of cachexia, sarcopenia and muscle · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundSarcopenia is associated with unfavourable long-term survival in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). However, the impact of myosteatosis and muscle loss on patient prognosis has not been investigated.
methodsSeven hundred fifty-six HCC patients who received LT at 3 transplant centres were included. Computed tomography (CT) images of recipients were collected to measure skeletal muscle index (SMI) and skeletal muscle radiodensity (SMRA). The impact of myosteatosis on the prognosis of sarcopenic and non-sarcopenic patients was studied separately. Muscle status was evaluated based on the presence of sarcopenia and myosteatosis. The muscle loss of 342 males was calculated as the relative change of SMI between pre- and post-LT evaluations. Cox regression models were used to identify predictors of overall survival (OS) and recurrence-free survival (RFS).
resultsThe study comprised 673 males and 83 females. The median follow-up time was 31 months (interquartile range, 19-43 months). Prior to LT, 267 (39.7%) and 187 (27.8%) males were defined as sarcopenic (low-SMI) and myosteatotic (low-SMRA), respectively. For sarcopenic recipients, the presence of myosteatosis was followed by a 23.6% decrease in 5 year OS (P < 0.001) and a 15.0% decrease in 5 year RFS (P = 0.014). Univariate and multivariate analyses revealed that muscle status was an independent predictor of OS [hazard ratio (HR), 1.569; 95% confidence interval (CI), 1.317-1.869; P < 0.001] and RFS (HR, 1.369; 95% CI, 1.182-1.586; P < 0.001). Postoperatively, a muscle loss >14.2% was an independent risk factor for poor OS (HR, 2.286; 95% CI, 1.358-3.849; P = 0.002) and RFS (HR, 2.219; 95% CI, 1.418-3.471; P < 0.001) in non-sarcopenic recipients (N = 209).
conclusionsPre-transplant myosteatosis aggravated the adverse impact of sarcopenia on liver transplant outcomes in male HCC patients. Post-transplant muscle loss might assist in prognostic stratification of recipients without pre-existing sarcopenia, intriguing new insights into individualized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.